Huebner, Hanna
Ruebner, Matthias
Kurbacher, Christian
Hadji, Peyman
Hartkopf, Andreas D.
Lux, Michael P.
Huober, Jens
Uhrig, Sabrina
Taran, Florin-Andrei
Overkamp, Friedrich
Tesch, Hans
Häberle, Lothar
Lüftner, Diana
Wallwiener, Markus
Müller, Volkmar
Beckmann, Matthias W.
Hein, Alexander
Belleville, Erik
Untch, Michael
Janni, Wolfgang
Fehm, Tanja N.
Kolberg, Hans-Christian
Wallwiener, Diethelm
Brucker, Sara Y.
Schneeweiss, Andreas
Ettl, Johannes
Fasching, Peter A. http://orcid.org/0000-0003-4885-8471
Michel, Laura L.
Funding for this research was provided by:
Friedrich-Alexander-Universität Erlangen-Nürnberg
Article History
Received: 26 July 2022
Accepted: 30 October 2022
First Online: 21 November 2022
Declarations
:
: E.B. has received honoraria from Novartis, Celgene, EISAI, Daiichi Sankyo, Merrimack, AstraZeneca, Riemser, Pfizer, Hexal, Amgen, and onkowissen.de for consulting, clinical research management, or medical education activities. J.E. has received honoraria from Roche, Celgene, Novartis, Pfizer, Lilly, Pierre Fabre, Teva, and Tesaro, as well as travel support from Celgene, Novartis, Lilly, Pfizer, Teva, and Tesaro. P.A.F. has received honoraria from Roche, Pfizer, Novartis, and Celgene; his institution conducts research for Novartis. A.D.H. has received honoraria from Teva, Genomic Health, Celgene, AstraZeneca, Novartis, Pfizer, and Roche. C.K. has received honoraria from Amgen, Roche, Teva, Novartis, MSD, Axios, and Riemser. H.C.K. has received honoraria from Carl Zeiss meditec, Teva, Theraclion, Novartis, Amgen, AstraZeneca, Pfizer, Janssen-Cilag, GSK, LIV Pharma, Roche, MSD, SurgVision, Onkowissen, and Genomic Health. H.H. received speaker honorary from LEO Pharma. M.P.L. has received honoraria from Lilly, Pfizer, Roche, MSD, Hexal, Novartis, AstraZeneca, Eisai, Exact Sciences, Daiichi-Sankyo, Grünenthal, Gilead, Pierre Fabre, PharmaMar, Samantree, Sysmex, pfm and medac for advisory boards, lectures, and travel support. V.M. has received speaker honoraria from Amgen, AstraZeneca, Celgene, Daiichi Sankyo, Eisai, Pfizer, Pierre Fabre, Novartis, Roche, Teva, and Janssen–Cilag, and consultancy honoraria from Genomic Health, Roche, Pierre Fabre, Amgen, Daiichi-Sankyo, and Eisai. F.O. has received speaker and consultancy honoraria from Amgen, AstraZeneca, Bayer, BMS, Boehringer, Celgene, Chugai, Eisai, Gilead, Hexal, Ipsen, Janssen, Merck, MSD, Novartis, Novonordisc, Riemser, Roche, Servier, Shire, Tesaro, and Teva. P.H. has received honoraria, unrestricted educational grants, and research funding from Amgen, AstraZeneca, Eli Lilly, MSD, Novartis, Pfizer, and Roche. A.S. has received honoraria from Roche, Celgene, AstraZeneca, Novartis, Pfizer, Zuckschwerdt Verlag GmbH, Georg Thieme Verlag, Aurikamed GmbH, MCI Deutschland GmbH, bsh medical communications GmbH, and promedicis GmbH. H.T. has received honoraria from Novartis, Roche, Celgene, Teva, and Pfizer, as well as travel support from Roche, Celgene, and Pfizer. M.W. has received speaker honoraria from AstraZeneca, Celgene, Roche, MSD and Novartis. F.A.T. has received honoraria from AstraZeneca, Genomic Health, Novartis, Roche, Tesaro, and Teva, as well as travel support from Novartis and Tesaro. D.L. has received honoraria from Amgen, Loreal, Pfizer, Novartis, Eli Lilly, Samsung, Celgene, Astra Zeneca, Teva and GSK. All remaining authors have declared that they have no conflicts of interest.
: This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of the Medical Faculty, University of Tübingen, Tübingen, Germany (protocol code 234/2014BO1, first approval on June 17, 2014, approval of Amendment 1 on June 11, 2015, approval of Amendment 2 on March 18, 2019).
: Informed consent was obtained from all individual participants included in the study.